# Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant

> **NCT00288028** · PHASE1 · COMPLETED · sponsor: **Barbara Ann Karmanos Cancer Institute** · enrollment: 15 (actual)

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **DRUG:** bortezomib

## Key facts

- **NCT ID:** NCT00288028
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2010-11
- **Final completion:** 2012-06
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2013-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00288028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00288028, "Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00288028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*